FDA considers adding a dozen peptides to its bulk drug compounding list RAPS Peptides are starting to move back into the conversation., After years of restriction under the FDAs 503A Category 2 list, were now seeing momentum toward re evaluation and potential reintroduction FDA to review broader access to restricted peptides in July FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner RFK Jr. may make it easier to get peptides what do doctors think? FDA mulls compounding for peptides previously flagged over safety risks BioSpace